Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941432 | 1.00 | AGBL2 (0.43) | AGBL2ADORA2ASLC22A12SYKDPP4 | |
| SCHEMBL29475250 | 0.83 | AGBL2 (0.41) | AGBL2ADORA2A | |
| SCHEMBL4973249 | 0.83 | AGBL2 (0.41) | AGBL2ADORA2A | |
| SCHEMBL30519756 | 0.83 | AGBL2 (0.41) | AGBL2ADORA2A | |
| SCHEMBL23874363 | 0.78 | SLC22A12 (0.41) | AGBL2SLC22A12ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL24420107 | 0.78 | AGBL2 (0.41) | AGBL2ADORA2ADPP4 | |
| SCHEMBL9952921 | 0.78 | PLAU (0.36) | L3MBTL1MAPK1 | |
| SCHEMBL22980910 | 0.78 | AGBL2 (0.41) | AGBL2 | |
| SCHEMBL1577538 | 0.78 | HTT (0.34) | AGBL2ALDH1A1 | |
| SCHEMBL15544538 | 0.78 | AGBL2 (0.62) | AGBL2DPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115057811-B | Preparation method of 2-bromomethyl-3, 5-difluoropyridine | 安庆朗坤药业有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115057811-A | Preparation method of 2-bromomethyl-3, 5-difluoropyridine | 安庆朗坤药业有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-119454711-A | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119176794-A | Heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| CN-115484952-B | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003005-A1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011003012-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2231646-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | ENPP2, PLP2, PDXK | AGBL2 1181/4885ADORA2A 1412/4885SLC22A12 3544/4885 |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | AGBL2 3421/4885ADORA2A 1575/4885SLC22A12 3004/4885 |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | AGBL2 1503/4885ADORA2A 182/4885SLC22A12 2106/4885 |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | AGBL2 1831/4885ADORA2A 229/4885SLC22A12 2480/4885 |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | AGBL2 3268/4885ADORA2A 665/4885SLC22A12 2945/4885 |
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, HTR1E | AGBL2 1534/4885ADORA2A 107/4885SLC22A12 3390/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | AGBL2 2675/4885ADORA2A 1753/4885SLC22A12 3711/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | AGBL2 1148/4885ADORA2A 1050/4885SLC22A12 3460/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | AGBL2 4162/4885ADORA2A 1090/4885SLC22A12 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.